At a glance
Overview
This monthly dashboard expands on the weekly COVID-19, flu, and RSV data available. It allows users to take a deeper dive into attitudes and behaviors associated with COVID-19, flu, and RSV vaccine uptake by a comprehensive set of demographic characteristics, behavioral and social drivers of vaccination, and barriers to vaccination.
Methods
Vaccination coverage estimates among adults 18 years and older are based on data from CDC's National Immunization Survey–Fall Respiratory Virus Module. Estimates of vaccination coverage are based on respondent self-report. Estimates of vaccination coverage on this dashboard may vary from estimates on the weekly dashboard: weekly estimates are derived from compiling interview data from all prior weeks, while monthly estimates are derived only from interviews conducted that month.
Data Summary
COVID-19 vaccine
- As of October 2025, 8.7% of adults 18+ years, 10.9% of adults 18 – 64 years with high-risk conditions, and 19.7% of adults 65+ years in the U.S. had received a 2025–26 COVID-19 vaccine.
- 17.0% of adults 18+ years, 23.2% of adults 18 – 64 years with high-risk conditions, and 25.0% of adults 65+ years reported that they definitely will get vaccinated with a 2025–26 COVID-19 vaccine.
- Nationally, adults who expressed moderate to high concern about getting COVID-19 disease are more likely to have received a 2025–26 COVID-19 vaccine compared with adults who expressed little to no concern (16.1% vs. 4.4%). Adults who considered the vaccine safe and who considered the vaccine important to protect them are also more likely to have received the 2025–26 COVID-19 vaccine (16.4% vs. 1.5% and 14.3% vs. 0.4%, respectively).
- The percent of adults reporting a healthcare provider had recommended COVID-19 vaccination this season was 15.7%.
Influenza vaccine
- As of October 2025, 24.0% of adults 18+ years in the U.S. had received a 2025–26 flu vaccine.
- Coverage was lower among Hispanic adults (20.4%) compared with other race/ethnicities.
- 22.6% of adults reported that they definitely will get vaccinated with a 2025–26 influenza vaccine.
- Nationally, adults who expressed moderate to high concern about getting flu are more likely to have received a 2025–26 flu vaccine compared with adults who expressed little to no concern (31.7% vs. 20.5%). Adults who considered the vaccine safe and who considered the vaccine important to protect them are also more likely to have received the 2025–26 vaccine (34.2% vs. 9.1% and 32.8% vs. 4.0%, respectively).
- The percent of adults reporting a healthcare provider had recommended flu vaccination this season was 37.3%.
RSV vaccine
- As of October 2025, RSV vaccination coverage was 38.2% among adults aged 75+ years and 29.4% among those aged 50–74 years at increased risk of severe RSV disease.
- Among adults aged 75 years, 8.9% reported that they definitely will be vaccinated against RSV; among those aged 50–74 years at increased risk, 18.8% reported that they definitely will be vaccinated.
- RSV vaccination coverage was lower among White, non-Hispanic adults (41.3%) compared with other races and ethnicities, among adults aged ≥75 years (e.g., 20.2% among Hispanic adults).
- Nationally, adults aged 75+ years who expressed moderate to high concern about getting RSV were more likely to have received an RSV vaccine compared with adults who expressed little to no concern (49.1% vs. 32.1%). Adults who considered the vaccine safe and who considered the vaccine important to protect them were also more likely to have received the RSV vaccine (63.9% vs. 15.5% and 54.6% vs. 5.7%, respectively).
- The percent of adults reporting a healthcare provider had recommended RSV vaccination was 35.6% among adults aged 75+ years and 35.7% among those aged 50–74 years at increased risk of severe RSV disease.